Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN® (plitidepsin) in Australia and New Zealand.
Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory and sales milestones achieved by APLIDIN® (plitidepsin).
PharmaMar will retain production rights and will supply the finished product to STA for exclusive commercial use in Australia and New Zealand.
APLIDIN® (plitidepsin) is PharmaMar´s second anticancer drug candidate obtained from a marine organism. This first in class drug is currently in development for the treatment of multiple myeloma and a type of T cell lymphoma. The company announced in June that patient recruitment of the international pivotal Phase III trial (ADMYRE) for APLIDIN® (plitidepsin) in refractory/relapsed multiple myeloma was successfully completed.
Specialised Therapeutics Australia Chief Executive Officer Mr. Carlo Montagner said: "Multiple myeloma remains relatively rare, but it is an insidious disease with one of the lowest survival rates in oncology.
"There is a desperate need for new therapies and all data to date suggests APLIDIN® could become a first in class, novel drug to potentially improve therapeutic tools for multiple myeloma patients.
"This drug is a welcome addition to STA's expanding oncology portfolio and we look forward to making this treatment option available to patients in Australia and New Zealand, pending the release of pivotal Phase 3 data confirming its efficacy.
"We applaud PharmaMar's commitment in developing this important therapy and are delighted to collaborate with a partner of this calibre."
Jose Maria Fdez. Sousa-Faro,Chairman of PharmaMar said: "Our commitment to bringing innovative therapies to all patients continues, and this collaboration with a strong pharmaceutical group in Australia and New Zealand is crucial for the role of the anticancer drug plitidepsin in these two important territories."
Specialised Therapeutics Australia